Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Inoue, K. Nakata, T. Arai, E. Yamaguchi, T. Ichiwata, M. Ebina, R. Tazawa, H. Ishii, Y. Setoguchi, M. Kitaichi, M. Akira, K. Tatsumi, Y. Nasuhara, K. Cho, Y. Tsuchihashi, K. Uchida, T. Takada, H. Nakayama, K. Tomii, C. Sugimoto, Y. Kohashi, S. Ohkouchi, Y. Kasahara, K. Morimoto, N. Sakamoto (Osaka, Niigata, Nagoya, Tokyo, Sendai, Chiba, Hokkaido, Nagasaki, Kobe, Japan). Occupational and environmental impact on the clinical course of autoimmune pulmonary alveolar proteinosis. Eur Respir J 2012; 40: Suppl. 56, 1772

Member's Comments

No comment yet.

Related content which might interest you: Occupational exposures associated with pulmonary alveolar proteinosis Source: International Congress 2017 – Shared exposures related to interstitial disease and airflow obstruction Year: 2017 Intercurrent intractable factors in autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Clinical and paraclinical manifestations of pulmonary alveolar proteinosis in children Source: Eur Respir J 2007; 30: Suppl. 51, 402s Year: 2007 Revisiting the role of pulmonary surfactant in chronic inflammatory lung diseases and environmental exposure Source: Eur Respir Rev, 30 (162) 210077; 10.1183/16000617.0077-2021 Year: 2021 Possible ocular involvement in pulmonary alveolar proteinosis Source: Eur Respir J 2006; 28: 456 Year: 2006 Comorbid interstitial lung diseases and collagen vascular diseases in pulmonary alveolar proteinosis: a nationwide surveillance in Japan Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Clinical assessment and management of pulmonary alveolar proteinosis: the importance of a reference centre Source: Annual Congress 2009 - Pulmonary alveolar proteinosis: clearing the Milky Way Year: 2009 Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2012; 39: 777-780 Year: 2012 The impact of airborne occupational exposure in chronic obstructive pulmonary disease Source: Annual Congress 2010 - The impact of airborne occupational exposure in COPD Year: 2010 Surveillance of whole lung lavage for autoimmune pulmonary alveolar proteinosis in Japan Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Clinical and inflammatory features of exacerbations of occupational chronic obstructive pulmonary disease Source: International Congress 2017 – Shared exposures related to interstitial disease and airflow obstruction Year: 2017 Autoimmune pulmonary alveolar proteinosis complicated with infections: a nationwide surveillance study in Japan Source: International Congress 2017 – Rare diseases Year: 2017 Call for an international survey on therapeutic lavage for pulmonary alveolar proteinosis Source: Eur Respir J 2012; 39: 1049 Year: 2012 Pulmonary alveolar proteinosis Source: Respipedia Article Year: 2017 Autoimmune pulmonary alveolar proteinosis complicated with sarcoidosis: clinical courses and serum levels of anti-GM-CSF autoantibody Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Occupational risk factors and idiopathic pulmonary fibrosis. A case-control study Source: Annual Congress 2007 - The air we breathe at home and at work Year: 2007 Cross-sectional and longitudinal measurement of autoantibody levels against GM-CSF is useful for predicting clinical courses of in autoimmune pulmonary alveolar proteinosis. Source: International Congress 2017 – Rare diseases Year: 2017 Incidence of autoimmune pulmonary alveolar proteinosis estimated using Poisson distribution Source: ERJ Open Res, 5 (1) 00190-2018; 10.1183/23120541.00190-2018 Year: 2019